Abigail Gregor Featured in Bloomberg Law “They’ve Got Next: 40 Under 40” Series

Practices: Intellectual Property, Intellectual Property Transactions, IP Structuring in M&A, Spinouts & Reorganizations, Strategic Licensing Programs, Life Sciences Licensing, Collaborations & Joint Ventures, Joint Ventures, Collaborations and Alliances, IP-Backed Finance, Strategic Commercial Agreements Industries: Healthcare & Life Sciences Tags: Women Attorneys

Life sciences licensing partner Abigail Gregor was honored in Bloomberg Law’sThey’ve Got Next: 40 Under 40” in the Healthcare and Life Sciences category. The Bloomberg Law series features attorneys under the age of 40 who are doing consequential work in their practice areas.

In the profile article, Abigail describes some of her most substantial legal work including representing Blackstone in its $2 billion financing collaboration with Alnylam - a complex transaction with multiple deals rolled into one (a royalty monetization, a product financing, an equity component, and a debt component)—all on an expedited timeline. She also cited her work for ImmunoGen in its worldwide exclusive license with Eli Lilly for up to $1.7 billion under ImmunoGen’s novel technology to advance antibody-drug conjugates directed to certain Lilly-selected targets.

The article notes that in addition to her transactional work with pharmaceutical, biotech and medical device companies, Abigail is active in pro bono initiatives such as the Innocence Project. She is a board member of the Women’s Bar Foundation of Massachusetts, which provides free legal counseling and representation in civil legal matters for low-income women and children.


Cookie Settings